Fig. 3: CXCR5+CD8+T is associated with superior response to ACT. | Nature Communications

Fig. 3: CXCR5+CD8+T is associated with superior response to ACT.

From: Intratumoral CXCR5+CD8+T associates with favorable clinical outcomes and immunogenic contexture in gastric cancer

Fig. 3

a, b Survival curves for the use of ACT (±RT) in patients with high/low CD8+T/CXCR5+CD8+T cell infiltration in the a ZSHS and b ACRG cohorts. HRs of disease mortality for patients with ACT (±RT) versus without according to tumor CD8+T/CXCR5+CD8+T cell infiltration and interaction between the biomarker and treatment were reported. The response to ACT (±RT) analysis was conducted in patients with TNM II + III stage diseases. P value shown resulted from the comparison between with and without ACT (±RT) treatment of n = 343 (ZSHS TNM II + III cohort) and n = 161 (ACRG TNM II + III cohort) patients with gastric cancer, using the Kaplan–Meier method followed by log-rank statistical test; the unadjusted and adjusted HRs and 95% CIs are reported. #Sample size too small to conduct multivariate Cox analysis. Source data are provided as a Source data file. ZSHS Zhongshan Hospital, ACRG Asian Cancer Research Group, HR hazard ratio, CI confidence interval, ACT adjuvant chemotherapy, RT radiotherapy.

Back to article page